Duration of Tamoxifen Use and the Risk of Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers

PURPOSE: Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of approximately 80%. Tamoxifen treatment of the first cancer has been associated with a reduction in the risk of a subsequent contralateral cancer. METHODS: We studied 1504 women with a known BRCA1 or BRCA2 mutat...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Gronwald, Jacek, Robidoux, Andre, Kim-Sing, Charmaine, Tung, Nadine, Lynch, Henry T., Foulkes, William D., Manoukian, Siranoush, Ainsworth, Peter, Neuhausen, Susan, Demsky, Rochelle, Eisen, Andrea, Singer, Christian F., Saal, Howard, Senter, Leigha, Eng, Charis, Weitzel, Jeffrey, Moller, Pal, Gilchrist, Dawna M., Olopade, Olufunmilayo, Ginsburg, Ophira, Sun, Ping, Huzarski, Tomasz, Lubinski, Jan, Narod, Steven A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4131437/
https://ncbi.nlm.nih.gov/pubmed/24951267
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-014-3026-3
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller